• Only two prescriptions (RESTASIS® from Allergan Corporation, Xiidra® from Shire) are used in the global market. I have it.
• Given that GBT-201 is a new drug developed as a prescription drug and there are not many competing products, the market demand for the new drug is very high, given the very limited treatment techniques of the two products (RESTASIS®, Xiidra®) currently dominating the market.
